CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

UroGen Pharma Ltd.

URGN
$2.00BSmall Cap

Next catalyst

PDUFAJun 14, 2027in 204 days

UGN-103

recurrent low-grade intermediate-risk non–muscle invasive bladder cancer

Get an email about URGN's next catalysts

Track UroGen Pharma (URGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 3 readout, earnings).See the timeline

Catalyst Timeline

3 upcoming, 1 past

Phase 3

UGN-104 Phase 3 Est. Readout

March 2027~UGN-10470

Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carcinoma

Source
Earnings

URGN Earnings Report

Jun 14, 2027

EPS Est: $0.05 | FQ end Sep/2026 | Call: bmo

PDUFANext

FDA PDUFA Date UGN-103

Jun 14, 2027UGN-103

For recurrent low-grade intermediate-risk non–muscle invasive bladder cancer. nda filing. AI-extracted from news: <![CDATA[FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC]]>

Source

Upcoming FDA decisions

How URGN's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaRA'ANANA287 employees
Drug Pipeline

Frequently asked questions

What is in UroGen Pharma Ltd.'s drug pipeline?→

CatalystAlert tracks 5 drug candidates in UroGen Pharma Ltd.'s (URGN) pipeline across Phase 3, Phase 2. Its lead program is UGN-103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is UroGen Pharma Ltd.'s next FDA catalyst?→

UroGen Pharma Ltd.'s (URGN) next tracked catalyst is a PDUFA date expected Jun 14, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track URGN biotech catalysts?→

Add URGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UroGen Pharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply